Aelis Farma
Agent28Agent Readiness: 28/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.
About
Aelis Farma is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain and peripheral disorders by targeting the CB1 receptor. Their proprietary platform generates Signaling Specific inhibitors of the CB1 receptor (CB1-SSi), which mimic a natural brain defense mechanism to treat various neurological conditions without disrupting normal behavior. The company's lead candidates, AEF0117 and AEF0217, are in advanced clinical trials for cannabis use disorders and cognitive deficits, respectively.
Key facts
At-a-glance profile data
- Website
- aelisfarma.com
- Headquarters
- Bordeaux, Nouvelle-Aquitaine, France
- Founded
- 2013
- Employees
- 25
- Total funding
- $49M (Grant)
- Business model
- B2B
Funding rounds
Tech stack
Detected on aelisfarma.com, last scanned 25 Sept 2026. Run your own scan
- Frontend
- Nuxt, Tailwind CSS
- Hosting
- OVHcloud
Frequently asked
How much funding has Aelis Farma raised?
Aelis Farma has raised a total of $49M in funding. The most recent round on record is Grant.
How many employees does Aelis Farma have?
Aelis Farma has approximately 25 people on record.